The efficacy of vildagliptin in korean patients with type 2 diabetes

about

The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.

P2860

Q38442291-4A274C51-E91A-4E25-BDC2-2DFD538FDEC9

P2860

The efficacy of vildagliptin in korean patients with type 2 diabetes

Item

http://www.wikidata.org/entity/Q38452916

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

The efficacy of vildagliptin in korean patients with type 2 diabetes

@en

type

Item

label

The efficacy of vildagliptin in korean patients with type 2 diabetes

@en

prefLabel

The efficacy of vildagliptin in korean patients with type 2 diabetes

@en

P1476

The efficacy of vildagliptin in korean patients with type 2 diabetes

@en

P2093

Jun Sung Moon

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.

Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.

Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.

Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.

Hypoglycemia and cardiovascular risks

P304

36-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.4093/DMJ.2013.37.1.36

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kyu Chang Won

P577

2013-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235730852

http://www.w3.org/2001/XMLSchema#string

P698

23441298

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3579150

http://www.w3.org/2001/XMLSchema#string

The efficacy of vildagliptin in korean patients with type 2 diabetes

about

P2860

P2860

The efficacy of vildagliptin in korean patients with type 2 diabetes

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932